"I am excited": 21-year-old Jane Mndebele becomes the first South African to receive lenacapavir
History was made in the Mpumalanga province of South Africa on Friday, 5 June, as 21-year-old Jane Mndebele became the first person to receive lenacapavir, the twice-yearly HIV prevention injectable, as part of the country's new national prevention programme.
Young people in Asia and the Pacific are helping shape a Prevention Revolution 2.0
When Jeremy Tan from Youth LEAD talks about HIV prevention among young people, he starts with where you can actually find them: online, in private messages, on dating apps and in community spaces.
UNAIDS welcomes expanded rollout of HIV prevention medicine and calls for urgent action to ensure equitable and affordable global access
GENEVA, 15 April 2026—UNAIDS commends the Global Fund to Fight AIDS, TB and Malaria and the United States for their commitment to further increase access to long-acting HIV prevention medication. In a recent statement they pledged to increase their initial ambition of reaching 2 million with lenacapavir, twice yearly injections which prevent HIV, to reach 3 million people by 2028.
New Access Framework for the new era of HIV prevention calls for scaled-up investments, expanded choice and sustainability to achieve 2030 targets
The HIV response is at a tipping point. If HIV prevention is deprioritized and defunded, gains made in stopping new HIV infections could be reversed.
HIV ‘Prevention Hangout’ expands information and HIV services at Brazil’s 2026 Salvador Carnival
During the 2026 Carnival in Salvador de Bahia—one of the largest street festivals in Brazil, which gathered around 12 million people—UNAIDS, the Municipal Health Secretariat of Salvador, Bahia, and the non-governmental organization Motirô BA provided HIV information, testing and prevention services to its participants through the “Rolê da Prevenção” initiative.
Multisectoral resilience to funding cuts in Guatemala
In 2025, cuts in international support for the HIV response in Guatemala and a reduced HIV allocation from the Global Fund caused immediate challenges for the HIV response. Some services were curtailed or discontinued altogether in clinics affected by the cuts, and remaining service providers struggled to absorb clients who had lost their service access. Furthermore, a substantial portion of the personnel at HIV comprehensive care units and community outreach workers that help facilitate and…
South Africa charts a new frontier by rolling out a twice-yearly injection which is almost 100% effective in preventing HIV
UNAIDS welcomes the announcement of new deals to make new HIV prevention medicines available and affordable for people in need
UNAIDS strongly welcomes the announcement of two new agreements to advance progress in stopping new HIV infections. UNAIDS estimates show that 1.3 million people were infected with HIV in 2024 far higher than the target of 370,000 by 2025. Lenacapavir, produced by US company Gilead, is a revolutionary new medicine that prevents HIV infection with injections just twice a year.
UNAIDS welcomes new WHO guidelines on Lenacapavir
Lenacapavir–a long-acting, six-monthly injectable antiretroviral medicine manufactured by Gilead Sciences–is now recommended by the World Health Organization as an additional HIV prevention choice as part of combination HIV prevention approaches.
